Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.

Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE, Caligiuri M, Lohr JB, Reist C. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006 Feb; 7(2):119-33.

View in: PubMed

subject areas

Antipsychotic Agents
Dyskinesia, Drug-Induced
Humans
Patents as Topic
Pharmacogenetics
Risk Factors
Schizophrenia

authors with profiles

Lawrence J. Albers, MD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support